Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or... – Inactivation or attenuation; producing viral subunits
Reexamination Certificate
2006-12-19
2006-12-19
Parkin, J. S. (Department: 1648)
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
Inactivation or attenuation; producing viral subunits
C435S237000, C424S215100
Reexamination Certificate
active
07150984
ABSTRACT:
The present invention provides vaccine compositions of attenuated human rotavirus. More particularly, the attenuated human rotavirus is produced by cold passage and thus contains attenuating mutations which produce virus having a cold-adapted (ca) and temperature sensitive (ts) phenotype. The attenuated strains are used in methods for stimulating the immune system of an individual to induce protection against human rotavirus by administration of the ca attenuated rotavirus.
REFERENCES:
patent: 4571385 (1986-02-01), Greenberg et al.
patent: 4624850 (1986-11-01), Albert et al.
patent: 4927628 (1990-05-01), Chanock et al.
patent: 5147639 (1992-09-01), Welter et al.
patent: 5298244 (1994-03-01), Redmond et al.
Glass R, Gentsch J, Smith J; Rotavirus vaccines: Success by Reassortment; Science 265: 1389-1391, Sep. 1994.
Kapikian A,Hoshino Y,Flores J,Midthun K, Glass R,Nakagomi O,Nakagomi T,Chanock R,Potash L,Levine M, Dolin R,Wright P,Belshe R,Anderson E,Vesikari T,Gothefors L,Wadell G,Perez-Schael I; Alternative approaches to the development of a rotavirus vaccine; 11th NoBel Conf., Stockholm: 192-214, 1985.
Bernstein D, Smith V, Sander D, Pax K, Schiff G, Ward R; Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants; J. Infect. Dis. 162:1055-1062, 1990.
Matsuno S, Murakami S, Takagi M, Hayashi M, Inouye S, Hasegawa A, Fukai K; Cold-adaptation of human rotavirus; Virus Res. 7:273-280, 1987.
Vesikara T, Ruuska T, Koivu H, Green K, Flores J, Kapikian A; Evaluation of the M37 human rotavirus vaccine in 2- to 6-month-old infants; Pediatr. Infect. Dis. J. 10(12):912-917, 1991.
Lerner et al., in The biology of immunologic disease; eds. Dixon F and Fisher D; HP Publishing Inc:331-338, 1983.
Greenberg et al., “Rescue of Noncultivatable Human Rotavirus by Gene Reassortment During Mixed Infection with ts Mutants of a Cultivatable Bovine Rotavirus,”Proc. Natl. Acad. Sc.USA 78:420-424 (Jan. 1981).
Kalica et al., “Genes of Human Strain WA and Bovine Strain UK Rotaviruses that Code for Neutralizaiton and Subgroup Antigens,” Biosys Abstract No. 82:149917 (1981).
Gombold et al., “Assignment of Simian Rotavirus SA11 Temperature-sensitive Mutant Groups B and E to Genome Segments,” Medline Abstract No. 86045886 (May 1985).
Wyatt et al., “Human Rotavirus Type 2: Cultivation In Vitro,”Science207: 189-191 (1980).
Vesikari et al., “Immunogenicity and Safety of Live Oral Attenuated Bovine Rotavirus Vaccine Strain RIT 4237 in Adults and Young Children,”Lancet2:807-811 (1983).
Lerner et al., “The Development of Synthetic Vaccines”, inThe Biology of Immunology Disease, Dixon and Fisher, eds., HP Publishing Co., pp. 331-338 (1983).
Hoshino et al., “Independent Segregation of Two Antigenic Specificities (VP3 and VP7) involved in Neutralization of Rotavirus Infectivity,”Proc. Natl. Acad. Sci. USA82:8701-8704 (1985).
Kapikian et al., “Rhesus Rotavirus: A Candidate Vaccine for Prevention of Human Rotavirus Disease,”Vaccine 85, Eds. Lerner et al., Cold Spring Harbor Laboratory, NY, pp. 357-367 (1985).
Midthun et al., “Reassortant Rotaviruses as Potential Live Rotavirus Vaccine Candidates,”J. Virol.53:949-954 (1985).
Shaw et al., “Specific Enzyme-Linked Immunoassay for Rotavirus Serotypes,”J. Clin. Microbiol.22:286-291 (1985).
Midthun et al., “Single Gene Substitution Rotavirus Reassortants Containing the Major Neutralization Protein (VP7) of Human Rotavirus Serotype 4,”J. Clin. Microbiol.24:822-826 (1986).
Clark et al., “Response of Adult Human Volunteers to Oral Administration of Bovine and Bovine/Human Reassortant Rotaviruses,”Vaccine4:25-31 (1986).
Offit et al., “Identification of the Two Rotavirus Genes Determining Neutralization Specificities,”J. Virol.57:376-378 (1986).
Clark et al., “Immune Response of Infants and Children to Low-Passage Bovine Rotavirus (Strain WC3),”Am. J. Dis. Child.140:350-356 (1986).
Matsuno et al., “Cold-Adaption of Human Rotavirus,”Virus Res.7:273-280 (1987).
Taniguchi et al., “Direct Serotyping of Human Rotavirus in Stools by an Enzyme-Linked Immunosorbent Assay Using Serotype 1-, 2-, 3-, and 4-Specific Monoclonal Antibodies to VP7,”J. Infect. Dis.155:1159-1166 (1987).
Hoshino et al., “Infection Immunity of Piglets to Either VP3 of VP7 Capsid Protein Confers Resistance to Challenge with a Virulent Rotavirus Bearing the Corresponding Antigen,”J. Virol.62:744-748 (1988).
Kapikian et al., “Development of a Rotavirus Vaccine by a “Jennerian” and a Modified “Jennerian” Approach,”Vaccines 88, p. 151-159 (1988).
Flores et al., “Reactions to and Antigenicity of Two Human-Rhesus Rotavirus Reassortant Vaccine Candidates of Serotypes 1 and 2 in Venezuelan Infants,”J. Clin. Microbiol.27:512-518 (1989).
Bernstein et al., “Evaluation of WC3Rotavirus Vaccine and Correlates of Protection in Healthy Infants,”J. Infect. Dis.162:1055-1062 (1990).
Green et al., “Homotypic and Heterotypic Epitope-Specific Antibody Responses in Adult and Infant Rotavirus Vaccinees: Implications for Vaccine Development,”J. Infect. Dis.161:667-679 (1990).
Flores et al., “Comparison of Reactogenicity and Antigenicity of M37 Rotavirus Vaccine and Rhesus-Rotavirus-Based Quadrivalent Vaccine,”Lancet2:330-334 (1990).
Padilla-Noriega et al., “Diversity of Rotavirus Serotypes in Mexican Infants with Gastroenteritis,”J. Clin. Microbiol.28:1114-1119 (1990).
Perez-Schael et al., “Clinical Studies of a Quadrivalent Rotavirus Vaccine in Venezuelan Infants,”J. Clin. Microbiol.28:553-558 (1990).
Vesikari et al., “Evaluation of the M37 Human Rotavirus Vaccine in 2- to 6-Month-Old Infants,”Pediatr. Infect. Dis.10:912-917 (1991).
Kapikian et al., “An Update on the “Jennerian” and Modified “Jennerian” Approach to Vaccination of Infants and Young Children against Rotavirus Diarrhea,”Adv. Exp. Med. Biol., 327:59-69 (1992).
Vesikari, “Clinical Trials of Live Oral Rotavirus Vaccines: the Finish Experience,”Vaccines 9311:255-261 (1993).
Hoshino et al., “Genetic Determinants of Rotavirus Virulence Studied in Gnotobiotic Piglets,”Vaccines, pp. 277-282 (1993).
Dennehy et al., “Safety and Efficacy of an Oral Tetravalent Rhesus Rotavirus Vaccine (RRV-TV) in Healthy Infants,” Abst. No. 1052,APS-SPR(1994).
Glass et al., “Rotavirus Vaccines: Success by Reassortment?”Science, 265:1389-1391 (Sep. 2, 1994).
Chanock Robert M.
Hoshino Yasutaka
Kapikian Albert Z.
Parkin J. S.
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Attenuated human rotavirus vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attenuated human rotavirus vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated human rotavirus vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3654393